Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Phase-II Study of MK-1029 added to Montelukast in Adults with Uncontrolled Asthma
To demonstrate that MK-1029, compared with placebo, increases lung function when added to montelukast.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A clinical trial to test if the combination of ertugliflozin with Sitagliptin is safe when compared to placebo in patients with Type 2 Diabetes whose sugar levels are not well controlled by diet and excercise
In subjects with T2DM and inadequate glycemic control on diet and exercise, after 26 weeks: 1. To assess the A1C-lowering efficacy of ertugliflozin 15 mg q.d. plus sitagliptin 100 mg q.d. relative to...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
After 30 weeks, in elderly patients with T2DM with inadequate glycemic control on diet and exercise: 1) To assess the effect of sitagliptin compared with glimepiride on A1C. 2) To assess the effe...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A clinical trial to test if the drug ertugliflozin is safe and effective when compared to placebo in patients with Type 2 Diabetes and stage 3 chronic kidney disease whose sugar levels are not well controlled by their current treatment
In subjects with T2DM and inadequate glycemic control on standard diabetes therapy with a Visit 3/Week -2 eGFR of ≥30 to <60 mL/min/1.73m2, after 26 weeks: 1. To assess the A1C-lowering efficacy of t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Phase IIa trial of MK0646 Tx in combo w/ Irinotecan vs Cetuximab and Irinotecan for mRC patients
To compare PFS of patients with wtKRAS mRC with High IGF-1/Low IGF-2 levels when treated with Dalo + Irino relative to patients treated with Cetux + Irino
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA
Update Il y a 5 ans
A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment-Naïve and Prior Treatment Failure to Pegylated Interferon and Ribavirin Patients with Chronic Genotype 1 Hepatitis C Virus Infection
To evaluate the antiviral activity of each of the four arms of MK-5172(arms 1, 2, 3, and 4) administered in combination with Peg-IFN alfa-2b and RBV as assessed by the proportion of patients achieving...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) compared with the addition of a licensed drug Glimepiride) in patients with Type 2 Diabetes
1. to assess the A1C-lowering efficacy of MK-3102 compared with glimepiride. 2. To assess the safety and tolerability of MK-3102.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
In patients with primary hypercholesterolemia and high cardiovascular risk with LDL-C ≥100 mg/dL (2.59 mmol/L) and ≤160 mg/dL (4.14 mmol/L), to evaluate: 1) at the end of Phase I, the additional LDL...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Effects of Depth of Neuromuscular Blockade and Insufflation Pressure on Surgical Conditions
The primary objective of the trial is to assess the benefit of deep neuromuscular blockade in surgical conditions when compared to standard neuromuscular blockade in patients undergoing elective in-pa...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Phase III Study of Pembrolizumab (MK 3475) plus Best Supportive Care in Subjects with Advanced Hepatocellular Carcinoma
1. Objective: To compare progression-free survival (PFS) per RECIST 1.1 assessed by a blinded central imaging vendor. 2. Objective: To compare OS between pembrolizumab plus BSC versus placebo plus ...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
7
8
9
10
11
12
13
14
15
16
Next